Cambridge Investment Research Advisors
ZS icon

Cambridge Investment Research Advisors’s Zscaler ZS Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ZS Stock Details ZS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27M Sell
23,148
-569
-2% -$79.3K 0.01% 1316
2026
Q1 		$3.33M Buy
23,717
+3,223
+16% +$572K 0.01% 1220
2025
Q4 		$4.61M Sell
20,494
-1,560
-7% -$440K 0.01% 977
2025
Q3 		$6.61M Buy
22,054
+699
+3% +$199K 0.02% 761
2025
Q2 		$6.7M Buy
21,355
+647
+3% +$161K 0.02% 708
2025
Q1 		$4.11M Sell
20,708
-3,226
-13% -$643K 0.01% 901
2024
Q4 		$4.32M Sell
23,934
-1,509
-6% -$292K 0.01% 884
2024
Q3 		$4.35M Buy
25,443
+8,066
+46% +$1.47M 0.01% 874
2024
Q2 		$3.34M Buy
17,377
+1,628
+10% +$290K 0.01% 971
2024
Q1 		$3.03M Sell
15,749
-4,106
-21% -$919K 0.01% 1022
2023
Q4 		$4.4M Buy
19,855
+7,817
+65% +$1.45M 0.02% 765
2023
Q3 		$1.87M Buy
12,038
+672
+6% +$101K 0.01% 1180
2023
Q2 		$1.66M Buy
11,366
+154
+1% +$18.8K 0.01% 1285
2023
Q1 		$1.31M Sell
11,212
-623
-5% -$74.7K 0.01% 1392
2022
Q4 		$1.32M Buy
11,835
+201
+2% +$27.3K 0.01% 1325
2022
Q3 		$1.91M Sell
11,634
-4,960
-30% -$811K 0.01% 1064
2022
Q2 		$2.48M Buy
16,594
+6,759
+69% +$1.2M 0.01% 940
2022
Q1 		$2.37M Sell
9,835
-11,597
-54% -$2.85M 0.01% 1036
2021
Q4 		$6.89M Sell
21,432
-2,899
-12% -$913K 0.03% 516
2021
Q3 		$6.38M Buy
24,331
+4,667
+24% +$1.17M 0.03% 508
2021
Q2 		$4.25M Buy
19,664
+1,987
+11% +$378K 0.02% 704
2021
Q1 		$3.04M Sell
17,677
-1,410
-7% -$280K 0.02% 795
2020
Q4 		$3.81M Buy
19,087
+2,746
+17% +$437K 0.02% 618
2020
Q3 		$2.3M Buy
16,341
+6,810
+71% +$884K 0.02% 735
2020
Q2 		$1.04M Buy
9,531
+2,675
+39% +$222K 0.01% 1101
2020
Q1 		$417K Sell
6,856
-137
-2% -$7.54K ﹤0.01% 1478
2019
Q4 		$325K Buy
6,993
+686
+11% +$31.8K ﹤0.01% 1856
2019
Q3 		$298K Sell
6,307
-3,364
-35% -$242K ﹤0.01% 1829
2019
Q2 		$741K Buy
9,671
+4,726
+96% +$337K 0.01% 1203
2019
Q1 		$351K Buy
+4,945
New +$263K ﹤0.01% 1715

Other funds holding ZS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Cambridge Investment Research Advisors's ZS Position: Q2 2026 in Review

Cambridge Investment Research Advisors reduced its Zscaler (ZS) stake by 2.4% in Q2 2026, selling an estimated $79.3K and leaving 23,148 shares worth $3.27M. The position accounts for 0.01% of the portfolio, ranked #1316.

Cambridge Investment Research Advisors first reported a position in ZS in Q1 2019 and has held it in 30 quarters since. The position peaked at $6.89M in Q4 2021. 742 funds tracked by Wall St. Rank hold ZS as of Q2 2026.

  • Cambridge Investment Research Advisors held 23,148 shares of Zscaler worth $3.27M as of Q2 2026.
  • Cambridge Investment Research Advisors sold 569 Zscaler shares in Q2 2026, an estimated $79.3K.
  • Zscaler made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #1316 holding.
  • Cambridge Investment Research Advisors first reported a position in Zscaler in Q1 2019 and has held it in 30 quarters since.
  • Cambridge Investment Research Advisors's Zscaler position peaked at $6.89M in Q4 2021.
  • 742 funds tracked by Wall St. Rank held Zscaler as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.